Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net loss	$ (146,412)	$ (162,857)	$ (146,398)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	18,439	12,537	12,758
Amortization and impairment of intangible assets	3,732	78,312	11,637
Amortization of operating lease right-of-use assets	6,650	6,149	6,499
Stock-based compensation	55,792	67,581	64,183
Fair value (gain) loss on contingent consideration and investments	4,529	(64,727)	(8,018)
Other	(3,331)	(19,708)	2,237
Changes in operating assets and liabilities:
Research fees and grants receivable	(55,623)	(75,119)	(45,933)
Income taxes (payable) receivable	(29,843)	6,651	30,464
Accounts payable and accrued liabilities	3,457	10,635	(15,104)
Deferred revenue	(2,195)	(7,931)	(13,976)
Deferred grant income	(3,638)	33,967	39,521
Other assets	17,148	5,954	18,253
Net cash used in operating activities	(131,295)	(108,556)	(43,877)
Cash flows from investing activities:
Purchases of property and equipment	(42,772)	(78,396)	(76,947)
Purchase of marketable securities	(436,044)	(765,086)	(1,021,510)
Proceeds from marketable securities	506,072	937,882	910,937
Receipt of grant funding	21,343	35,708	25,311
Distribution from equity accounted investees	30,113	0	0
Investment in and loans to equity accounted investees	(7,137)	(19,626)	(13,690)
Proceeds from repayment of loan from joint venture partner	33,268	0	0
Long-term investments and other assets	(17,093)	10,927	(45,209)
Net cash provided by (used in) investing activities	87,750	121,409	(221,108)
Cash flows from financing activities:
Payment of liability for in-licensing agreement and other	(15,649)	(729)	(1,234)
Proceeds from long-term liabilities and other	29,731	13,498	11,590
Net cash provided by financing activities	14,082	12,769	10,356
Effect of exchange rate changes on cash and cash equivalents	1,097	(2,617)	589
Increase (decrease) in cash and cash equivalents	(28,366)	23,005	(254,040)
Cash and cash equivalents and restricted cash, beginning of period	183,615	160,610	414,650
Cash and cash equivalents and restricted cash, end of period	155,249	183,615	160,610
Restricted cash included in other assets	1,736	2,290	2,290
Total cash, cash equivalents, and restricted cash shown on the balance sheet	153,513	181,325	158,320
Supplemental disclosure of non-cash investing and financing activities
Property and equipment in accounts payable	1,995	12,767	13,625
Right-of-use assets obtained in exchange for operating lease obligation	$ 76,118	$ 1,898	$ 1,199

AbCellera Biologics Inc. 10-K